EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq: ADLR) announced today the initiation of a third Phase 2a study of ADL5859, a novel Delta opioid agonist in development for the treatment of pain. Study 33CL231 will explore the analgesic efficacy of ADL5859 in treating pain associated with diabetic peripheral neuropathy. Recently, Adolor and Pfizer Inc (NYSE: PFE) entered into a collaboration to develop and commercialize two Delta opioid agonist compounds, including ADL5859, for the treatment of a wide range of inflammatory, neuropathic and acute pain conditions.
